[14 CO2 exhalation in patients with substituted primary myxedema following oral application of C14 caprylic acid or C-14 trioctanoate].
D000328:Adult; D002210:Caprylates / Q000008:administration & dosage / Q000378:metabolism*; D002245:Carbon Dioxide / Q000032:analysis*; D002247:Carbon Isotopes; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009230:Myxedema / Q000188:drug therapy* / Q000378:metabolism; D012119:Respiration; D013535:Suspensions; D013963:Thyroid Hormones / Q000627:therapeutic use
D002210:Caprylates; D002247:Carbon Isotopes; D013535:Suspensions; D013963:Thyroid Hormones; D002245:Carbon Dioxide
Die 14CO2-Exhalation bei Kranken mit substituiertem primärem Myxödem nach oraler Verabreichung von 14C-Caprylsäure oder 14C-Trioctanoat.